Stock PAR PARADIGM BIOPHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Paradigm Biopharmaceuticals Limited

Equities

PAR

AU000000PAR5

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:06 2024-07-16 am EDT 		5-day change 1st Jan Change
0.3 AUD 0.00% Intraday chart for Paradigm Biopharmaceuticals Limited +3.45% -29.41%
Apr. 19 Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program MT
Feb. 28 Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 269.1 708 482.8 224.2 278.9 105.1 - -
Enterprise Value (EV) 1 269.1 604.2 412.5 224.2 278.9 105.1 105.1 105.1
P/E ratio -12.8 x -51.5 x -12.5 x -5.72 x -4.76 x -1.49 x -4.84 x -4.11 x
Yield - - - - - - - -
Capitalization / Revenue 82,908,610 x 150,773,056 x 53,994,726 x 2,829,779,033 x 5,965,328,828 x - - -
EV / Revenue 82,908,610 x 150,773,034 x 53,994,718 x 2,829,779,033 x 5,965,328,828 x - - -
EV / EBITDA -31 x -58.7 x -14.2 x -5.74 x -5.39 x -1.45 x -3.39 x -2.06 x
EV / FCF -42.2 x -69.3 x -13.8 x -6.96 x -6.17 x -1.46 x -3.45 x -2.41 x
FCF Yield -2.37% -1.44% -7.24% -14.4% -16.2% -68.5% -29% -41.6%
Price to Book 3.25 x 6.54 x 6.17 x 5.31 x 5.2 x 9.68 x 7.14 x 6.98 x
Nbr of stocks (in thousands) 192,208 224,747 229,906 232,306 281,757 350,364 - -
Reference price 2 1.400 3.150 2.100 0.9650 0.9900 0.3000 0.3000 0.3000
Announcement Date 8/30/19 8/27/20 8/26/21 8/25/22 8/25/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 3.246 4.695 8.942 0.0792 0.0468 - - -
EBITDA 1 -8.69 -12.05 -34.05 -39.03 -51.74 -72.5 -31 -51
EBIT 1 -8.699 -12.26 -34.26 -39.22 -51.89 -72.5 -31 -51
Operating Margin -268.01% -261.2% -383.14% -49,508.9% -110,978.61% - - -
Earnings before Tax (EBT) 1 -15.63 -12.3 -34.3 -39.25 -51.91 -72 -30.5 -50.5
Net income 1 -15.63 -12.3 -34.3 -39.25 -51.91 -72 -30.5 -50.5
Net margin -481.49% -261.93% -383.57% -49,545.04% -111,013.71% - - -
EPS 2 -0.1093 -0.0612 -0.1674 -0.1687 -0.2078 -0.2010 -0.0620 -0.0730
Free Cash Flow 1 -6.383 -10.22 -34.96 -32.21 -45.19 -72 -30.5 -43.7
FCF margin -196.66% -217.6% -390.98% -40,652.95% -96,634.47% - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 8/30/19 8/27/20 8/26/21 8/25/22 8/25/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2021 S1 2021 S2 2022 S1 2022 S2
Net sales - - - -
EBITDA - -13.44 - -
EBIT 1 - -13.55 - -12.25
Operating Margin - - - -
Earnings before Tax (EBT) - - - -
Net income -20.73 - -26.99 -
Net margin - - - -
EPS -0.0910 - -0.1180 -
Dividend per Share - - - -
Announcement Date 2/24/21 8/26/21 2/23/22 8/25/22
1AUD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - 104 70.3 - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -6.38 -10.2 -35 -32.2 -45.2 -72 -30.5 -43.7
ROE (net income / shareholders' equity) -10.5% -15.5% -36.8% - - - - -
ROA (Net income/ Total Assets) - -16.1% - - - - - -
Assets 1 - 76.44 - - - - - -
Book Value Per Share 2 0.4300 0.4800 0.3400 0.1800 0.1900 0.0300 0.0400 0.0400
Cash Flow per Share 2 - -0 -0.1700 - -0.1600 0.0200 0.0400 0.0400
Capex - 0.13 0.03 - - - - -
Capex / Sales - 2.79% 0.34% - - - - -
Announcement Date 8/30/19 8/27/20 8/26/21 8/25/22 8/25/23 - - -
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3 AUD
Average target price
0.47 AUD
Spread / Average Target
+56.67%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PARADIGM BIOPHARMACEUTICALS LIMITED Stock Paradigm Biopharmaceuticals Limited
-29.41% 71.24M
MODERNA, INC. Stock Moderna, Inc.
+24.45% 46.56B
LONZA GROUP AG Stock Lonza Group AG
+45.04% 41.67B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.99% 41.16B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+34.87% 32.4B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+21.10% 28.18B
CELLTRION, INC. Stock Celltrion, Inc.
-6.35% 28.1B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+49.46% 14.52B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+47.93% 13.74B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.09% 12.17B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PAR Stock
  4. Financials Paradigm Biopharmaceuticals Limited